These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 32898238)

  • 1. Sustained Responses of Neutralizing Antibodies Against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Recovered Patients and Their Therapeutic Applicability.
    Kim YS; Aigerim A; Park U; Kim Y; Park H; Rhee JY; Choi JP; Park WB; Park SW; Kim Y; Lim DG; Choi JY; Jeon YK; Yang JS; Lee JY; Shin HS; Cho NH
    Clin Infect Dis; 2021 Aug; 73(3):e550-e558. PubMed ID: 32898238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longevity of seropositivity and neutralizing antibodies in recovered MERS patients: a 5-year follow-up study.
    Cheon S; Park U; Park H; Kim Y; Nguyen YTH; Aigerim A; Rhee JY; Choi JP; Park WB; Park SW; Kim Y; Lim DG; Yang JS; Lee JY; Kim YS; Cho NH
    Clin Microbiol Infect; 2022 Feb; 28(2):292-296. PubMed ID: 34139334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015.
    Choe PG; Perera RAPM; Park WB; Song KH; Bang JH; Kim ES; Kim HB; Ko LWR; Park SW; Kim NJ; Lau EHY; Poon LLM; Peiris M; Oh MD
    Emerg Infect Dis; 2017 Jul; 23(7):1079-1084. PubMed ID: 28585916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultrapotent Human Neutralizing Antibody Repertoires Against Middle East Respiratory Syndrome Coronavirus From a Recovered Patient.
    Niu P; Zhang S; Zhou P; Huang B; Deng Y; Qin K; Wang P; Wang W; Wang X; Zhou J; Zhang L; Tan W
    J Infect Dis; 2018 Sep; 218(8):1249-1260. PubMed ID: 29846635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in the Spike Protein of Middle East Respiratory Syndrome Coronavirus Transmitted in Korea Increase Resistance to Antibody-Mediated Neutralization.
    Kleine-Weber H; Elzayat MT; Wang L; Graham BS; Müller MA; Drosten C; Pöhlmann S; Hoffmann M
    J Virol; 2019 Jan; 93(2):. PubMed ID: 30404801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
    Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
    Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superior immune responses induced by intranasal immunization with recombinant adenovirus-based vaccine expressing full-length Spike protein of Middle East respiratory syndrome coronavirus.
    Kim MH; Kim HJ; Chang J
    PLoS One; 2019; 14(7):e0220196. PubMed ID: 31329652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein.
    Li Y; Wan Y; Liu P; Zhao J; Lu G; Qi J; Wang Q; Lu X; Wu Y; Liu W; Zhang B; Yuen KY; Perlman S; Gao GF; Yan J
    Cell Res; 2015 Nov; 25(11):1237-49. PubMed ID: 26391698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus.
    Choi JH; Woo HM; Lee TY; Lee SY; Shim SM; Park WJ; Yang JS; Kim JA; Yun MR; Kim DW; Kim SS; Zhang Y; Shi W; Wang L; Graham BS; Mascola JR; Wang N; McLellan JS; Lee JY; Lee H
    PLoS One; 2020; 15(5):e0232757. PubMed ID: 32384116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization and Demonstration of the Value of a Lethal Mouse Model of Middle East Respiratory Syndrome Coronavirus Infection and Disease.
    Tao X; Garron T; Agrawal AS; Algaissi A; Peng BH; Wakamiya M; Chan TS; Lu L; Du L; Jiang S; Couch RB; Tseng CT
    J Virol; 2016 Jan; 90(1):57-67. PubMed ID: 26446606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-Protection against MERS-CoV by Prime-Boost Vaccination Using Viral Spike DNA and Protein.
    Choi JA; Goo J; Yang E; Jung DI; Lee S; Rho S; Jeong Y; Park YS; Park H; Moon YH; Park U; Seo SH; Lee H; Lee JM; Cho NH; Song M; Kim JO
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32967955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing Monoclonal Antibodies as Promising Therapeutics against Middle East Respiratory Syndrome Coronavirus Infection.
    Han HJ; Liu JW; Yu H; Yu XJ
    Viruses; 2018 Nov; 10(12):. PubMed ID: 30513619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus.
    Corti D; Zhao J; Pedotti M; Simonelli L; Agnihothram S; Fett C; Fernandez-Rodriguez B; Foglierini M; Agatic G; Vanzetta F; Gopal R; Langrish CJ; Barrett NA; Sallusto F; Baric RS; Varani L; Zambon M; Perlman S; Lanzavecchia A
    Proc Natl Acad Sci U S A; 2015 Aug; 112(33):10473-8. PubMed ID: 26216974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody.
    Houser KV; Broadbent AJ; Gretebeck L; Vogel L; Lamirande EW; Sutton T; Bock KW; Minai M; Orandle M; Moore IN; Subbarao K
    PLoS Pathog; 2017 Aug; 13(8):e1006565. PubMed ID: 28817732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus.
    Jung SY; Kang KW; Lee EY; Seo DW; Kim HL; Kim H; Kwon T; Park HL; Kim H; Lee SM; Nam JH
    Vaccine; 2018 Jun; 36(24):3468-3476. PubMed ID: 29739720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-dose treatment with a humanized neutralizing antibody affords full protection of a human transgenic mouse model from lethal Middle East respiratory syndrome (MERS)-coronavirus infection.
    Qiu H; Sun S; Xiao H; Feng J; Guo Y; Tai W; Wang Y; Du L; Zhao G; Zhou Y
    Antiviral Res; 2016 Aug; 132():141-8. PubMed ID: 27312105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform.
    Malczyk AH; Kupke A; Prüfer S; Scheuplein VA; Hutzler S; Kreuz D; Beissert T; Bauer S; Hubich-Rau S; Tondera C; Eldin HS; Schmidt J; Vergara-Alert J; Süzer Y; Seifried J; Hanschmann KM; Kalinke U; Herold S; Sahin U; Cichutek K; Waibler Z; Eickmann M; Becker S; Mühlebach MD
    J Virol; 2015 Nov; 89(22):11654-67. PubMed ID: 26355094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike protein.
    Chen Y; Lu S; Jia H; Deng Y; Zhou J; Huang B; Yu Y; Lan J; Wang W; Lou Y; Qin K; Tan W
    Emerg Microbes Infect; 2017 May; 6(5):e37. PubMed ID: 28536429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein.
    Widjaja I; Wang C; van Haperen R; Gutiérrez-Álvarez J; van Dieren B; Okba NMA; Raj VS; Li W; Fernandez-Delgado R; Grosveld F; van Kuppeveld FJM; Haagmans BL; Enjuanes L; Drabek D; Bosch BJ
    Emerg Microbes Infect; 2019; 8(1):516-530. PubMed ID: 30938227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.